Gene therapy has been applied to murine models of rheumatoid arthritis (RA) using a number of different strategies to downregulate inflammation in synovial joints. However, prolonged joint expression has been problematic. Our laboratory has found that early gestational intravascular injection of lentiviral vector leads to efficient transduction and sustained transgene expression in articular cartilage and synovium. In this study, we show that in utero gene transfer of IL-10 can prevent and decrease pathology in a murine model of RA. Following prenatal injection of lentiviral vector containing murine IL-10 gene, the cytokine was detectable in the serum, and the green fluorescent protein reporter gene was detectable in chondrocytes and synoviocytes of adult mice up to 21 weeks of age. Adult mice that had been treated prenatally were later immunized against type II collagen to induce an autoimmune arthritis. Compared with controls, prenatally treated mice demonstrated delayed onset of arthritis, decreased frequency of arthritis and markedly decreased severity of disease, by both clinical and histological criteria. This effect was directly related to levels of IL-10 expression, but no immunosuppressive effects of the therapy were observed. This study demonstrates proof of principle for the prenatal prevention and amelioration of RA by early gestational gene transfer of the anti-inflammatory cytokine, IL-
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes progressive destruction of the joints. Inflammation develops when monocytes and T lymphocytes invade the synovial lining, synovial fibroblasts proliferate, and erosion of the cartilage and underlying bone occurs. 1, 2 Several mouse models of RA exist, but collagen-induced arthritis (CIA) is the best studied, and manifests many of the same immunological and histopathological characteristics of the human disease. 3, 4 CIA is induced by intradermal injection of chicken-based type II collagen and Freund's adjuvant, and results in the production of anticollagen II IgG antibodies. Early in the disease, these antibodies enter the joint and form an immune complex with collagen II, activating the complement cascade. Increased permeability of the vascular endothelium allows macrophages and neutrophils to infiltrate the joint. 5 Macrophages are responsible for the production of tumor-necrosis factor-alpha (TNFa) and interleukin 1 (IL-1), which are key inflammatory mediators in the joint. 6 Chronic disease is maintained by autoreactive T cells.
Gene therapy has been applied to murine models of RA using a number of different strategies. These include the use of receptor antagonist to block the actions of TNFa and IL-1, anti-angiogenic strategies, and relevant to this study, overexpression of the antiinflammatory cytokines interleukin 10 (IL-10) and interleukin 4 (IL-4). 7, 8 IL-10 and IL-4 are known to inhibit TNFa and IL-1 production by synovial cells and suppress T helper 1 driven effects.
Specifically, IL-10 limits both innate and acquired immune responses by inhibiting the development of effector T cells and suppressing macrophage activity. 9 ,10 IL-10 also regulates the function and/or differentiation of several cell types, including B cells, natural killer cells, mast cells, dendritic cells and granulocytes. 11 Although human studies with IL-10 have not shown clinical efficacy, 12,13 IL-10 has been shown to decrease CIA in rodents by several different groups. [14] [15] [16] [17] [18] [19] [20] Previous attempts at IL-10 gene therapy in CIA mice have used a number of different vehicles (adenoviral and adeno-associated viral vectors or electrotransfer of plasmid DNA), and have tested both local (that is, intra-articular) and systemic (that is, intravascular or intramuscular) means of administration. 14, [16] [17] [18] [19] [20] Local joint expression often requires multiple injections and repeated doses of IL-10, whereas systemic delivery has generally been more effective but can cause immunosuppression and increased susceptibility to infection. 8 The mode of gene delivery can affect the level and duration of expression, and the host response to transgene. Lentiviral vector has been shown to efficiently transduce the synovium. 21 An ideal gene therapy for RA would act locally at the joints affected by RA, require a one-time transfer of the IL-10 gene, that is, have a long duration of action without immunogenicity, and avoid deleterious side effects. Although prenatal gene transfer is not yet practically applicable to RA, it satisfies many of these requirements.
The potential advantages of in utero gene transfer include fetal immunological tolerance, an increased vector particle to cell ratio, an increased frequency of stem cells and most importantly, increased accessibility of stem cell populations. 22 In this study, we utilized a new technique of early gestational intravascular injection at E9, to achieve sustained, high levels of IL-10 expression in cartilage and synovial tissue, consistent with the transduction of mesoderm-derived stem and/or progenitor cells. We demonstrate proof of principle that early gestational gene transfer of an anti-inflammatory cytokine by lentiviral vector can prevent or ameliorate arthritis pathology in a murine model.
RESULTS

Survival after E9 intracardiac injections
Animals were considered survivors if they were injected in utero and were still alive at 1 week of postnatal age. Using a green fluorescent protein (GFP) reporter in Balb/c mice, we observed a 38% (56/148 injected fetuses) survival after E9 intracardiac injection. With the CMV.IL-10.GFP vector in B10.QAi mice, 30% (51/168) of injected mice survived. The volume of the CMV.IL-10.GFP vector injected influenced survival rates: 47% (21/45) of fetuses injected with 560 nl survived compared with 22% (20/92) of fetuses injected with the full 700 nl dose.
Gross GFP expression after E9 intracardiac injections
A detailed description of the distribution of GFP expression after E9 intracardiac injections is beyond the scope of this study, and a detailed analysis will be published elsewhere. Briefly, the GFP expression can be predominantly seen in the heart, kidney, bones, cartilage and hematopoietic stem cells after E9 intracardiac injections with the CMV.IL-10.GFP vector (Figures 1a-d) . Control mice injected with the CMV-GFP vector showed a very similar transduction pattern (Supplementary Figure 1) .
Histological evidence of GFP expression and cartilage transduction GFP expression was analyzed in the distal joints of the forelimbs and hindlimbs (the hands and feet). GFP-positive chondrocytes (Figures 2a and c) and synovial fibroblasts (Figures 2b and d) were identified in the wrist and ankle joints of prenatally injected mice, but not in control mice (Supplementary Figure 2) . Up to 90% of chondrocytes and 80% of synovial fibroblasts were observed to be positive for GFP. The GFP fluorescence was distributed throughout all cartilage zones (Supplementary Figure 3) .
Serum cytokine levels
Three non-immunized adult mice were used as controls (M0F, M2F, M5F). No IL-10 was detectable in control serum. In addition, one prenatally injected mouse with no detectable serum IL-10, which was attributed to a missed injection, was included in the control group (M1MR) ( Table 1) . Although it can be assumed that some baseline level of IL-10 was present in all mice, it was at a level too low to be detected by enzyme-linked immunosorbent assay (ELISA). Therefore, a serum level of 0 reflects the subthreshold limit of IL-10 detection by ELISA rather than an absolute absence of IL-10. Among the 12 experimental mice, serum IL-10 was elevated at baseline, and ranged from 785 to 3728 pg ml À1 (Table 1) . Serum IL-10 levels declined in the majority of IL-10-injected mice, but remained relatively constant or increased in four mice (M3MN, M1MB, M3ML and M1ML). The small differences in the volume of vector injected seemed to have no relation to the serum IL-10 level. Serum IL-1b, IL-6 and TNFa levels were undetectable by ELISA in all mice.
To evaluate the longevity of IL-10 expression in a non-immunized mouse, one mouse received only a phosphate-buffered saline injection after prenatal administration of the CMV.IL-10.GFP vector. There was a steady decline in serum IL-10 levels from 1 to 4 months of age (M0A , Table 1 ), declining from 1882 to 639 pg ml À1 , respectively. This may be related to the increase in blood volume and therefore volume of distribution with growth of the animal. No animal demonstrated loss of IL-10 expression during the duration of the study.
Cytokine expression in the joint by quantitative PCR analysis Knee joints were analyzed for local IL-10 expression by quantitative reverse transcriptase-PCR. All of the IL-10-injected mice had increased Figure 1 GFP expression in whole organs by stereoscopic fluorescent microscopy at 2 weeks of age after E9 intracardiac injection using the CMV.IL-10.GFP vector. GFP can be seen in the (a) kidney, (b) heart, (c) shoulder joint and (d) bone (rib). In (c), the scapula (asterisk), joint (arrowhead) and humerus (arrow) are labeled. Scale bar¼1 mm. IL-10 expression in the knee joints when compared with controls, but the level of expression varied and did not correlate with serum IL-10 expression (Figure 3 ). Even after repeating the quantitative PCR, there were no statistical differences in the knee joint expression of TNFa, IL-1b, or IL-6 between experimental mice and controls (Supplementary Figure 4 ).
Serum antibodies to type II collagen
On killing, all immunized control mice were found to have antibodies to type II collagen by serum ELISA (Table 1 ). All but two of the experimental mice had anti-collagen II antibody levels of at least 500 mg ml À1 (Table 1) .
Subjective clinical arthritis (disease onset, severity)
The mean subjective scores of the 4 control mice and 12 experimental mice were compared with 12 different time points following immunization ( Figure 4 ). The experimental mice had lower subjective clinical scores than control mice at all time points, and differences at all but two of the time points were statistically significant.
Onset of arthritis was defined by the development of a subjective score of 3 or more in at least one joint. Using this definition, all of the control mice developed arthritis, although the severity varied ( Figure 5a ). In all, 67% (8/12) of experimental mice never developed arthritis, and of the 33% that did, the day of onset was significantly later in the experimental mice as compared with controls. Mean day of onset of arthritis among control mice was 35.5 days post immunization versus 63.8 days for the four IL-10-injected mice that developed arthritis.
Mice were subjectively scored for arthritis up to 85 days post immunization, and the maximal subjective score for each mouse was compared (Figure 5b ). The mean maximal score for the control mice was 11.3. By comparison, the mean maximal score for the IL-10 injected mice was 1.9. These data were statistically significant.
Histological evidence of arthritis
Trichrome staining was used to assess inflammation histologically. For each mouse, the distal-most joints of each limb (two hands and two feet) were sectioned and subjectively scored by two blinded observers. The non-immunized control mouse showed no inflammation In utero gene therapy for rheumatoid arthritis JL Roybal et al ( Figure 6a ). Immunized control mice had pannus formation, cartilage erosion, bone destruction and loss of joint integrity (Figure 6b ). By comparison, the IL-10-treated mice had normal appearing joint spaces, comparable to the non-immunized control (Figure 6c ). Rarely, synovial hyperplasia was seen.
Comparing the average score for all four limbs among the control and IL-10-injected mice, the control mice had an average score of 2, whereas the IL-10-injected mice had an average score of 0.29 ( Figure 7 ). These data were statistically significant.
DISCUSSION
The results of this study demonstrate proof of principle that prenatal gene transfer of IL-10 can prevent and/or ameliorate an immunemediated arthritis through expression of IL-10 in the joints, and systemically. We have shown that (1) prenatal gene transfer of lentiviral vector can transduce cells in the synovial joints, leading to long-term transgene expression and (2) sustained IL-10 expression can prevent and suppress arthritis. Treated mice showed a decreased frequency of disease, delayed onset of disease and lower subjective arthritis scores (both clinical and histological).
Although not yet a clinical possibility, there are several potential advantages to in utero treatment of arthritis that prompted this study. Juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis (JIA), is commonly a polyarticular disease that requires treatment of multiple joints. Our early gestational intravascular injections achieve gene transfer simultaneously to cells of multiple synovial joints, resulting in sustained polyarticular IL-10 expression. Second, arthritis often presents in unpredictable flares, making prevention difficult. The timing of prenatal gene transfer would ensure that IL-10 is present before the onset of disease. Third, because of flares, postnatal treatment often requires repeated administration of the protective agent. However, a single prenatal injection leads to a sufficient level of IL-10 expression to protect the mouse from arthritis for the duration of this study, and potentially for the lifetime of the mouse.
An important and expected finding in this study was that IL-10 was detected both locally and systemically. It appears to have had a combined effect. Previous attempts to treat RA by gene therapy have generally produced either local or systemic effects, but rarely both. 14, [16] [17] [18] [19] [20] In one study, the IL-10 gene was expressed both locally and systemically after intra-articular and intra-peritoneal electrotransfer of the plasmid DNA, but systemic expression was more sustainable and therefore much more effective at decreasing arthritis. 15 The potential advantage of our system is that we create both a local and a systemic effect with just one prenatal injection by targeting multiple tissues and joints simultaneously. However, all tissues do not express IL-10 in this model presumably because of the tropism of our specific vector and the developmentally dependent accessibility of specific stem cell populations at E9. 23 There are advantages and disadvantages to systemic IL-10 expression for this indication. In humans, systemic disease is a debilitating variant of human JIA, and gene therapy that is directed solely at the joints may not address systemic disease. The CIA mouse model is limited in that it does not manifest extra-articular disease. Therefore, from a clinical perspective, combined local and systemic IL-10 expression would potentially ameliorate the pauciarticular, polyarticular and systemic variants of JIA.
The obvious disadvantage of systemic expression of IL-10 is the potential for systemic immunosuppression. However, in this study, we did not observe any adverse effects as a result of elevated IL-10 levels. There were no apparent developmental abnormalities, no significant weight differences between control and experimental mice, and no clinical infections. The concern that expression of IL-10 would predispose people to Th2 diseases, such as lupus, is valid. A number of cytokines, including IL-6, IL-10 and IL-17 have been found to be elevated in Systemic Lupus Erythematosus patients. 24 IL-10, produced by Th2 cells, has been shown to regulate growth and differentiation of B lymphocytes and antibody production. IL-10 has also been asso- In utero gene therapy for rheumatoid arthritis JL Roybal et al ciated with the production of autoantibodies. 25 Although we did not observe any immunosuppression, we cannot be sure that the elevation of IL-10 in our mice did not predispose them to Th2 diseases, such as lupus. IL-10 has been found to be elevated in patients with Systemic Lupus Erythematosus, but the cytokine has not been consistently shown to correlate with Systemic Lupus Erythematosus disease activity or clinical profile. [24] [25] [26] It has been shown that continuous administration of IL-10 from 4 until 38 weeks of age in lupus-prone New Zealand Black/White (NZB/W) F1 mice accelerated the onset of autoimmunity. 27 However, the same period of continuous IL-10 administration did not cause development of lupus-like autoimmunity in normal BALB/c mice. If this approach ever proves to be feasible clinically, further studies would obviously need to be done. Levels of autoantibodies for double-or single-stranded DNA to see if they are upregulated in IL-10-injected B10.QAi mice would be one approach. With regard to the systemic versus local effects, the observed levels of IL-10 protein in the serum were elevated in all experimental mice and remained elevated for the duration of the experiment. Similarly, IL-10 mRNA expression in the knee joints was elevated in all experimental mice when compared with controls. In the majority of mice, however, the level of IL-10 protein in the serum did not correlate with the level of mRNA in the joint. Local IL-10 expression was not assessed until the mice were killed, approximately 12 weeks following immunization. It is unlikely that the local IL-10 expression declined over time. We have repeatedly observed transgene expression present in adult mice for at least 6 months to more than 1 year after our in utero injections. 23, 28, 29 The more likely explanation for the variation in joint IL-10 as compared with serum IL-10 expression has to do with the timing of in utero injection. We have previously demonstrated that In utero gene therapy for rheumatoid arthritis JL Roybal et al the distribution of gene expression after in utero injection depends upon the developmental stage. 23 At E9, stem cells in the developing cartilage and hematopoietic system are accessible for gene transfer. However, E9 is composed of three Theiler stages (TS 14-16), 30 and not all fetuses from the same mother are at the same Theiler stage at the time of injection. We have detected hematopoietic stem cell transduction in mice injected at all three Theiler stages of E9. However, cartilage stem cell transduction seems to be more efficient at the earlier Theiler stage. It is possible that the mice with elevated IL-10 in both the cartilage and the serum were injected at TS14, while those with high serum IL-10 but low joint IL-10 were injected at TS15-16.
Our use of the ubiquitous CMV promoter resulted in IL-10 expression in joints, but also resulted in low level GFP and presumably IL-10 expression in other tissues. Although we did not observe any deleterious effects, as with any gene therapy, improved tissue specificity would be a desirable goal. Potentially useful, more targeted promoters include a disease-regulated IL-1/IL-6 inducible promoter 31 and a cartilage-specific type II collagen promoter. 32 The diseaseregulated promoter would have the advantage of turning on and off with inflammation, but may be less effective in pre-emptive control of arthritis. The cartilage-specific promoter would eliminate systemic IL-10 expression, but might provide less robust suppression in the absence of synovial expression. Greater specificity would likely be required using these or other approaches before clinical application.
We were surprised by the pro-inflammatory cytokine levels in the knee joints as assessed by quantitative reverse transcriptase-PCR. We expected to see a decrease in local IL-1b, IL-6 and TNFa in the experimental mice relative to controls. There are a few possible explanations. First, CIA does not affect all joints equally, and when it causes inflammation, it tends to act distally at the hands and feet before affecting the knees and/or elbows. Accordingly, the pro-inflammatory cytokines in the knee joints were not elevated in all of the control mice. Second, because IL-10 expression in knee joints varied among the experimental mice, we would expect to see a variation in the pro-inflammatory cytokines as well. It is important to note that the relative IL-10 expression levels far exceeded the relative proinflammatory cytokine expression levels. Serum IL-1b and TNFa expression were too low for detection in all mice, both control and experimental. This has been observed in a previous study of IL-10 gene therapy in arthritic mice. 14 This study uses a mouse model to demonstrate proof of principle for this approach, but it is clearly not a feasible clinical approach at this time. In humans, the genetic component of JIA as currently understood is very complex and likely multigenetic. 33 We cannot yet test for JIA prenatally, or accurately predict which fetuses are susceptible to the disease. However, advances in our understanding of the genetics of JIA might allow us to identify fetuses with a strong predisposition toward the disease, making a preventive strategy feasible within the next decade. A similar approach might also be considered for other autoimmune disorders (type I diabetes for instance) when, and if, a strong genetic propensity is identified. Thus, although this study is not clinically applicable at the present time, it is at least thought provoking with respect to future strategies to address genetic disorders.
Similarly, there is the question of how the timing of the prenatal injection in this mouse model compares with the human. E9 in mice correlates to approximately 8-9 weeks human gestation. 34 Because of the small size of the heart and the significant likelihood of injury or death from an intracardiac injection, this would not be a feasible clinical approach. However, it is conceivable that other approaches to the vascular system are possible. Vessels on the surface of the placenta or the cord itself could potentially be accessed at this early age by using a fetoscopic approach, but this will require the development of smaller, less invasive fetoscopes than are currently available. In addition to supporting the potential for prenatal therapy, however, this study supports the general approach of using gene therapy to achieve cytokine-based suppression of the inflammatory process in arthritis or other inflammatory disorders. Our study suggests that if methods can be developed to achieve efficient transduction and sustained expression of IL-10 from the cartilage and/or synovial tissues at any time in life, it would be an effective approach to prevent or treat arthritis.
In conclusion, early gestational intravascular injection of lentiviral vector can achieve transduction of cartilage and synovial tissues with sustained expression of IL-10. Using this approach, we demonstrated proof of principle for the prenatal prevention and amelioration of RA by an immunosuppressive cytokine. Mice subjected to arthritis showed decreased onset, frequency and severity of disease. Local and systemic IL-10 expression contributed to this effect. Diseaseregulated and/or tissue-specific IL-10 expression may improve the specificity of this approach.
MATERIALS AND METHODS Animals
B10.Q/Ai mice were purchased from Taconic (Hudson, NY, USA) and housed in the Laboratory Animal Facility of the Colket Translational Research Building at The Children's Hospital of Philadelphia. Mice were maintained in sterilized plastic micro-isolator cages and given sterilized standard laboratory chow and tap water ad libitum. Animals were mated for 12-18 h to achieve accurate time-dated pregnancies. The day of separation of male and female mice was taken as E0. All experimental protocols were reviewed and approved by The Institutional Animal Care and Use Committee at The Children's Hospital of Philadelphia, and followed guidelines set forth in the 'Guide for Care and Use of Laboratory Animals' by the National Institutes of Health.
Intracardiac vector injection in E9 mice
The Vevo 2100 system (Visualsonics, Toronto, Ontario, Canada) was used for intracardiac injection of E9 pregnant mice. Pregnant mice were anesthetized and the surgical procedure was performed as previously described, 23 with the following modifications. The fetuses were scanned using a 30-70 MHz probe. The fetuses were positioned to get clear views of the beating heart in B-mode. Under two-dimensional visualization, the micropipette tip was physically advanced through the uterine wall, and into the ventricle of the beating heart. To optimize survival, two different volumes of vector were tested. A volume of 560 or 700 nl of vector suspension was injected with an automated syringe. Once the laparotomy incision was closed, but while the mouse was still asleep, an analgesic was administered through subcutaneous injection. The overall time of the procedure was limited to 30 min, from incision until closure. To recover, each mouse was placed under a heat lamp until it was awake and moving. Following injection, mothers are examined daily until E20, at which time delivery is expected. Neonates are followed 4-5 times per week and survivors are counted once the pups reach 7 days of age.
Lentiviral vector design
A self-inactivating lentiviral vector expressing murine IL-10, driven by the CMV promoter, with GFP as a reporter was generated as previously described. 35 Briefly, a complementary DNA library was prepared from C57BL/6 bone marrow-derived dendritic cells cultured in the presence of lipopolysaccharide (1 mg ml À1 ), using TRIzol reagent and Superscript (Invitrogen, Carlsbad, CA, USA), as per manufacturer's recommendations. The mouse IL-10-coding domain was amplified with the forward primer 5¢-GCGGCCGCGGTACCATGCCTGGCTCAGCACTG-3¢ and the reverse primer 5¢-GCTAGCTTAGCTTTTCATTTTGATCATCATG-3¢, using standard methods and confirmed by sequence analysis (GenBank sequence accession number NM 010548). The flanking NotI and NheI sites were inserted to simplify cloning into the HIV-1-based transfer plasmid. The CS-CG HIV-1 transfer plasmid, modified as previously described, was used to generate a selfinactivating lentiviral vector. [36] [37] [38] [39] This lentiviral vector allows the expression of the enhanced GFP reporter gene (Clontech Laboratories, Mountain View, CA, USA) or IL-10 and enhanced GFP genes as a single transcript under the control of the human cytomegalovirus promoter. For bicistronic gene expression, the internal ribosome entry site, identical to that of the encephalomyocarditis virus, was inserted between the IL-10 gene and the enhanced GFP reporter. Vesicular stomatitis virus-G-protein-pseudotyped viral particles were generated by transfection into a 293T cell line, and titered as previously described. 40 CIA model and subjective scoring of clinical arthritis Prenatally injected (experimental) and non-injected (control) mice at 6-7 weeks of age were immunized against type II collagen derived from chicken sternal cartilage (Sigma, St Louis, MO, USA, Cat no. C9301), as previously described for the CIA model. 41 Mice were subjectively scored for clinical arthritis by three blinded observers using the described 16-point scale. 41 Scoring continued up to 85-100 days following immunization, at which point mice were killed for analysis.
Serum IL-10, IL-1b, TNFa and anti-CII antibody assays Serum samples were obtained from anesthetized animals by retro-orbital puncture at various time points. For cytokine ELISAs, serum was obtained from peripheral blood analyzed for IL-10, IL-1b and TNFa using Ready-SETGo! kits from eBioscience (eBioscience, San Diego, CA, USA). The anti-CII antibody ELISA was performed using a kit from MD Biosciences (MD Biosciences Inc., St Paul, MN, USA, Cat no. M036001).
Stereoscopic immunofluorescence for gross GFP expression
Gross tissues were analyzed for GFP expression by stereoscopic fluorescence microscopy (MZ16FA; Leica, Heerburg, Switzerland). To allow comparison of the fluorescence intensity, an exposure time of 1 s was used for all photographs.
Immunohistochemistry
After killing the mice, forelimbs and hindlimbs were fixed in neutral buffer formalin (Sigma), transferred to the histoprocessor (TP 1050, Leica) overnight and embedded in paraffin using a Tissue-Tek (Sakura Finetek USA, Torrance, CA, USA) paraffin embedder. Paraffin sections at 4-mm thickness were obtained using a paraffin microtome (Leica RM 2030, Leica Instruments, Wetzlar, Germany) and collected on Probe On slides (Fisher, Pittsburgh, PA, USA). For bright-field microscopy, sections were de-paraffined, rehydrated in distilled water, and stained with hematoxylin and eosin and Masson's trichrome stain using the protocols published in 'AFIP Laboratory methods in histotechnology' (1994). Slides were imaged using a Leica DMRBE Microscope.
To evaluate and localize GFP protein in the harvested tissues, slides were de-paraffinized and hydrated in distilled water, transferred to 0.3% H 2 O 2 in distilled water for 30 min at room temperature (RT), then rinsed in distilled water and immersed in 1% Sodium Borohydride (Sigma) for 30 min at RT to block the auto-fluorescence. After several washes in 0.1 M Phosphate-buffered saline (Sigma), sections were ready for the application of anti-GFP antibody (Invitrogen) at a concentration of 1:400 and were incubated overnight at 4 1C. The next day, slides were rinsed in phosphate-buffered saline for 10 min at RT, then incubated in secondary antibody, Alexa Fluor 488 F(ab) fragment (Invitrogen), at a concentration of 1:200 for 30 min at RT. Slides were washed in phosphate-buffered saline for 10 min at RT and coverslipped with 4' ,6' diamino-2-phenylindole2HCl (slowfade gold DAPI, Invitrogen). Slides were imaged using a LSM 510 confocal microscope (Zeiss, Oberkochen, Germany). To quantitate GFP-positive chondrocytes and synovial fibroblasts, cells were counted in10 high-power fields per limb.
Subjective scoring for histological arthritis
Trichrome sections were subjectively evaluated for arthritis by two blinded observers using the a 4-point scale of inflammation modified from a previously described 5-point scale: 42 0, normal; 1, inflammatory infiltrates and synovial hyperplasia; 2, pannus formation, cartilage erosion and bone destruction; 3, loss of joint integrity.
RNA isolation and reverse transcription
After killing the mice, knee joints were isolated and stored in RNAlater solution (Ambion, Austin, TX, USA) at À20 1C until use. Total cellular RNA from the knees of control and experimental mice was isolated using the RiboPure Kit (Ambion), according to the manufacturer's instructions. Purity of RNA was measured using the Biophotometer Plus (Eppendorf, Hauppauge, NY, USA). First-strand complementary DNA was prepared using the High Capacity Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions.
Quantitative reverse transcriptase-PCR for IL-10, IL-1b, IL-6 and TNFa expression in knee joints Previously prepared complementary DNA was stored at À20 1C until use. Fluorescent-labeled IL-10, IL-1b, IL-6, TNFa and Act B (housekeeping gene) TaqMan probes were used (Applied Biosystems, Carlsbad, CA, USA). The complementary DNA was pre-amped for the respective probes for 14 cycles. Typical 12-ml reactions contained 6 ml ABI Universal TaqMan Fast PCR Master Mix, 0.6 ml TaqMan probe, 1 ml single-strand DNA and water to 12 ml. Each sample's experimental PCR run was performed in triplicate. Simultaneous PCR was performed for negative control samples containing master mix and probes, as described above but no template DNA (15 wells per 96-well sample plate). Thermal cycling was performed on a Fast Real-Time Quantitative PCR machine (Applied Biosystems 7500 Software). Results were measured as, RQ, or the relative quantity of gene expression as compared with the endogenous control, ActB.
Statistical analysis
Statistical comparisons were performed with Mann-Whitney U-tests to compare non-parametric data for statistical significance. P-values less than 0.05 were considered significant.
